Model-informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitis Publication Model-informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitis This article describes how a model-informed drug development (MIDD) approach was used to support the…CertaraMarch 24, 2026
Regulatory horizons 2026: Clinical pharmacology strategy and regulatory expectations Blog Regulatory horizons 2026: Clinical pharmacology strategy and regulatory expectations Learn how regulatory expectations in clinical pharmacology are evolving and how to build a strategy…CertaraMarch 24, 2026
From Numbers to Narrative: Mastering the Art of PK Presentation Guide From Numbers to Narrative: Mastering the Art of PK Presentation Master PK data reporting with a structured guide to presenting pharmacokinetic results clearly and turning…CertaraMarch 20, 2026
Pediatric Drug Development and Pharmacometrics: Key Questions Sponsors Must Answer Guide Pediatric Drug Development and Pharmacometrics: Key Questions Sponsors Must Answer Download Certara’s expert guide on pharmacometrics and pediatric drug development. Learn how modeling, MIDD, and…CertaraMarch 19, 2026
Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026 Blog Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026 Explore how model-informed drug development and AI are advancing pharmacoequity and shaping the future of…CertaraMarch 11, 2026
Modeling Platinum-Induced Nephrotoxicity: A PK/TD Analysis of Calbindin and B2-Microglobulin Urinary Biomarkers Webinar Modeling Platinum-Induced Nephrotoxicity: A PK/TD Analysis of Calbindin and B2-Microglobulin Urinary Biomarkers CertaraMarch 9, 2026
Navigate GxP Compliance in the Cloud with Confidence Guide Navigate GxP Compliance in the Cloud with Confidence Master SaaS GxP compliance with risk-based computer system validation (CSV) aligned to GAMP 5, FDA,…CertaraMarch 6, 2026
ADC first-in-human (FIH) dose selection: Designing FIH studies for success Blog ADC first-in-human (FIH) dose selection: Designing FIH studies for success Optimize ADC First-in-Human Dose Selection with model-informed strategies and exposure–response insights to design safer, more…CertaraMarch 3, 2026
Apotekarsocieteten Clinical Pharmacology Strategies in Drug Development Conference Apotekarsocieteten Clinical Pharmacology Strategies in Drug Development Danielle PillsburyMarch 2, 2026